About Grifols
Grifols plasma-derived products are the result
of a rigorous methodology, the latest technology
and a highly qualified team of professionals.
To trust a product, you must first trust the people who manufacture it
Plasma-derived products have become vital medicines today, capable of saving lives and improving life-expectancy for many people suffering from numerous chronic illnesses and traumatic injury.
Grifols plasma-derived medicines:
a heritage of experience and innovation
The scientists Edwin J. Cohn and José A. Grífols at the 4th International Congress of Blood Transfusion. Lisbon, 1951.
Grifols has been present in the field of healthcare since 1940, creating innovative products and services based on the values of ethics and responsibility.In order to meet the individual needs of different healthcare professionals, the company is organized into three divisions: Bioscience, Diagnostic and Hospital.
The Bioscience division specializes in the research, development, manufacture and supply of high quality plasma-derived medicines with outstanding records of quality and safety.From its beginnings, Grifols’ passion for safety in plasma-based therapies is evidenced in its history of innovation:
GRIFOLS International Logistics Centre – Grange Castle Business Park, Dublin
1943: Grifols obtains the Spanish patent for the introduction of the blood plasma freeze drying system, allowing longer preservation.
1951: Dr. José Antonio Grífols Lucas develops the plasmapheresis technique, destined to become the standard technique for plasma collection.
1972: Manufacture of a single donor lyophilized cryoprecipitate.
1984: Manufacture of inactivated FVIII concentrate.
1989: The first double inactivated FVIII/VWF to be manufactured in the world.
1991: Creation of Biomat, a company which is separated from the plasma fractionation facilities, and is dedicated exclusively to the supply, testing and control of plasma.
1995: Launching of the PediGri® program providing transparency of information for Grifols plasma-derived products.
1996: Introduction of nucleic acid amplification techniques (NAT) for HCV in plasma minipools.
1997: NAT for HCV in fractionation pools, 2 years before legally required.
2002: Purchase of US company SeraCare, now named Biomat USA, including its 43 plasmapheresis centers and the central analysis laboratory located in Austin.
2006: FDA approval of an Immune Globulin Intravenous (Human), with seven validated steps with viral elimination capacity , including a 20 nm nanofiltration.
2009: Creation of the Grifols Academy of Plasmapheresis – Educational center in US which offers our employees a program of standardized education in the plasma sciences.
2011:Grifols acquires US company Talecris Biotherapeutics, Inc., making it the world’s third-largest producer of plasma-derived products and expanding the network of plasma donation centers.
2011: A second analysis laboratory was established in San Marcos, Texas, in order to increase the capacity of processing samples of plasma from Grifols donation centers in the US.
2014: Grifols opens the world’s largest and one of the most technologically advanced plasma fractionation facilities in North Carolina, USA.